Biological effects of statins in atherosclerosis;Gli effetti biologici delle statine nella malattia aterosclerotica

Trends in Medicine

Volumn 9, Issue 1, 2009, Pages 19-26

  Franzone, Anna ^a   Schiattarella, Gabriele Giacomo ^a   Capretti, Giuliana ^a   Sorrentino, Sabato ^a   Pironti, Gianluigi ^a   Sannino, Anna ^a   Perrino, Cinzia ^a   Esposito, Giovanni ^a   Chiariello, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Atherosclerosis; Pleiotropism; Restenosis; Statin

Indexed keywords

GELATINASE B; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVALONIC ACID; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; COMPETITIVE INHIBITION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; MOLECULAR DYNAMICS; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; STENT; THROMBOCYTE FUNCTION;

EID: 68049131571     PISSN: 15942848     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 5:1135-1143.
2. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 1995; 91:1472-1479.
3. Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham study. JAMA 1971; 215:1617-1625.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389. (Pubitemid 24365311)
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-1357.
7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
8. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-thanaverage cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158. (Pubitemid 36398384)
9. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809.
10. Brown BG, Zhao XQ, Sacco DE, et al. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87:1781-1791.
11. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94:1247-1254.
12. Indolfi C, Stabile E, Perrino C, et al. Mechanisms of restenosis after angioplasty and approach to therapy. Int J Mol Med 1998; 2:143-148.
13. Indolfi C, Cioppa A, Stabile E, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 2000; 35:214-221. (Pubitemid 30061283)
14. Haunstetter A, Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res 1998; 82:1111-1129. (Pubitemid 28311120)
15. Isner JM, Kearney M, Bortman S, et al. Apoptosis in human atherosclerosis and restenosis. Circulation 1995; 91:2703-2711.
16. Work LM, McPhaden AR, Pyne NJ, et al. Short-term local delivery of an inhibitor of Ras farnesyltransferase prevents neointima formation in vivo after porcine coronary balloon angioplasty. Circulation 2001; 104:1538-1543. (Pubitemid 32917348)
17. Laufs U, Marra D, Node K, et al. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999; 274:21926-21931. (Pubitemid 129519746)
18. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273:24266-24271. (Pubitemid 28435775)
19. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97:1129-1135. (Pubitemid 28152885)
20. Kouchi H, Nakamura K, Fushimi K, et al. Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells. Biochem Biophys Res Commun 1999; 264:915-920.
21. Porter KE, Naik J, Turner NA, et al. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002; 36:150-157. (Pubitemid 41122904)
22. Kalela A, Laaksonen R, Lehtimaki T, et al. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am J Cardiol 2001; 88:173-175, A176. (Pubitemid 32607707)
23. Chamley JH, Campbell GR, McConnell JD, et al. Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and in subculture. Cell Tissue Res 1977; 177:503-522. (Pubitemid 8036319)
24. Jones KD, Couldwell WT, Hinton DR, et al. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 1994; 205:1681-1687.
25. Arends MJ, McGregor AH, Toft NJ, et al. Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br J Cancer 1993; 68:1127-1133. (Pubitemid 23356664)
26. Arnaboldi L, Guzzetta M, Pazzucconi F, et al. Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. Pharmacol Res 2007; 56:503-508. (Pubitemid 350137771)
27. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84:413-428.
28. Knapp AC, Huang J, Starling G, et al. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis 2000; 152:217-227.
29. Massy ZA, Guijarro C. Statins: effects beyond cholesterol lowering. Nephrol Dial Transplant 2001; 16:1738-1741. (Pubitemid 32821398)
30. Indolfi C, Di Lorenzo E, Perrino C, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002; 106:2118-2124. (Pubitemid 35192819)
31. Thorburn J, Xu S, Thorburn A. MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. EMBO J 1997; 16:1888-1900. (Pubitemid 27170950)
32. Wang SM, Tsai YJ, Jiang MJ, et al. Studies on the function of rho A protein in cardiac myofibrillogenesis. J Cell Biochem 1997; 66:43-53. (Pubitemid 27284096)
33. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 1997; 96:3243-3247. (Pubitemid 27500133)
34. O'Brien KD, McDonald TO, Chait A, et al. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996; 93:672-682. (Pubitemid 26052452)
35. Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol 2005; 20:541-546.
36. Ortego M, Bustos C, Hernandez-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147:253-261. (Pubitemid 29512257)